On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
We are very excited to launch our new website! Please take a few moments to click around and explore...